Freenome, Inc. Common stock (FRNM) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $1.09B and a free-cash-flow yield of -23.8%. Nama's AI scorecard rates it Sell, 2.5 out of 10. On 12-month momentum it ranks in the rising band of its market.
AI scorecard
Sell · 2.5/10
Clearly negative, short of the bottom band. As of Nov 7, 2026.
Momentum
Rising · +49.4% over 12 months ex. last
Second-best fifth of its market on the past year's move.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-41.8%
How far the last close sits under the highest price of the past five years.
Market cap
$1.09B
Trailing P/E
—
Price / book
—
Price / sales
30.9
FCF yield
-23.8%
Dividend yield
—
Gross margin
0.0%
Operating margin
-2867.5%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
0.5
Exchange
NASDAQ
Sector
Healthcare
Industry
Diagnostics Research
FRNM analyst price target
Median target $17.00 from 5 analysts, ranging $17.00 – $21.00.
Nama's AI scorecard currently rates Freenome, Inc. Common stock Sell (2.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is the FRNM price target?
The median analyst price target from 5 analysts is $17.00, with a range of $17.00 – $21.00.
Is FRNM Shariah compliant?
Nama's AAOIFI-style screen reads Freenome, Inc. Common stock as Can't Tell. A figure the screen needs is missing, so it can't tell.